M
Mark L. Van Natta
Researcher at Johns Hopkins University
Publications - 133
Citations - 23476
Mark L. Van Natta is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Retinitis & Cytomegalovirus retinitis. The author has an hindex of 46, co-authored 125 publications receiving 19696 citations.
Papers
More filters
Journal ArticleDOI
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
David E. Kleiner,Elizabeth M. Brunt,Mark L. Van Natta,Cynthia Behling,Melissa J. Contos,Oscar W. Cummings,Linda D. Ferrell,Yao Chang Liu,Michael Torbenson,Aynur Unalp-Arida,Matthew M. Yeh,Arthur J. McCullough,Arun J. Sanyal +12 more
TL;DR: A strong scoring system and NAS for NAFLD and NASH with reasonable inter‐rater reproducibility that should be useful for studies of both adults and children with any degree ofNAFLD are presented.
Journal ArticleDOI
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal,Naga Chalasani,Kris V. Kowdley,Arthur J. McCullough,Anna Mae Diehl,Nathan M. Bass,Brent A. Neuschwander-Tetri,Joel E. Lavine,James Tonascia,Aynur Unalp,Mark L. Van Natta,Jeanne M. Clark,Elizabeth M. Brunt,David E. Kleiner,Jay H. Hoofnagle,Patricia R. Robuck +15 more
TL;DR: Vitamin E was superior to placebo for the treatment of nonalcoholic steatohepatitis in adults without diabetes, and significant benefits of pioglitazone were observed for some of the secondary outcomes.
Journal ArticleDOI
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more
TL;DR: Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification.
Journal ArticleDOI
Long-term effects of budesonide or nedocromil in children with asthma.
Stanley J. Szefler,Scott T. Weiss,James Tonascia,N. Franklin Adkinson,Bruce G. Bender,Reuben M. Cherniack,Michele Donithan,H William Kelly,J. Reisman,Gail G. Shapiro,Alice L. Sternberg,R.C. Strunk,Virginia S. Taggart,Mark L. Van Natta,Robert A. Wise,Margaret Wu,Robert S. Zeiger +16 more
TL;DR: In children with mild-to-moderate asthma, neither budesonide nor nedocromil is better than placebo in terms of lung function, but inhaled budesonides improves airway responsiveness and provides better control of asthma than placebo or nedOCromil.
Journal ArticleDOI
Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial
Joel E. Lavine,Jeffrey B. Schwimmer,Mark L. Van Natta,Jean P. Molleston,Jean P. Molleston,Karen F. Murray,Philip J. Rosenthal,Stephanie H. Abrams,Ann O. Scheimann,Arun J. Sanyal,Naga Chalasani,James Tonascia,Aynur Unalp,Jeanne M. Clark,Elizabeth M. Brunt,David E. Kleiner,Jay H. Hoofnagle,Patricia R. Robuck +17 more
TL;DR: Neither vitamin E nor metformin was superior to placebo in attaining the primary outcome of sustained reduction in ALT level in patients with pediatric NAFLD.